In recent years, GLP-1 agonist medications have exploded in popularity as a treatment in the management of blood glucose and weight. The metabolic benefit of this newer class of drugs, typically prescribed for people with diabetes, makes them an effective treatment for a variety of chronic conditions that can be improved with weight reduction. Most, but not all, of these medications are injectable and are available by prescription in the US under brand names such as Trulicity®, Ozempic®, Mounjaro®, Zepbound®, and Wegovy®.
The 2026 PRC National Health Survey finds that more than 1 in 10 American adults (13.2%) currently takes some type of GLP-1 medication to treat diabetes, cardiovascular disease, sleep apnea, and/or for weight loss.
Fill out the form below to download our National Health Survey brief.
